Literature DB >> 24966580

Expression of alpha smooth muscle actin in living donor liver transplant recipients.

Masataka Hirabaru1, Kyoko Mochizuki1, Mitsuhisa Takatsuki1, Akihiko Soyama1, Taiichiro Kosaka1, Tamotsu Kuroki1, Isao Shimokawa1, Susumu Eguchi1.   

Abstract

Recently, there have been reports from liver biopsies that showed the progression of liver fibrosis in liver transplant patients after the cessation of immunosuppression. Herein, we focused on activated hepatic stellate cells expressing alpha smooth muscle actin (α-SMA) to understand the correlation between immunosuppressant medication and liver fibrosis. The study enrolled two pediatric patients who underwent living donor liver transplantation and ceased immunosuppressant therapy. The number of α-SMA-positive cells in the specimens obtained by liver biopsy from these two patients showed a three-fold increase compared with the number from four transplanted pediatric patients who were continuing immunosuppressant therapy. In addition, the α-SMA-positive area evaluated using the WinRooF image processing software program continued to increase over time in three adult transplanted patients with liver fibrosis, and the α-SMA-positive area was increasing even during the pre-fibrotic stage in these adult cases, according to a retrospective review. Therefore, α-SMA could be a useful marker for the detection of early stage fibrosis.

Entities:  

Keywords:  Alpha smooth muscle actin; Hepatic stellate cells; Immunosuppressant therapy; Liver fibrosis; Living donor liver transplantation

Mesh:

Substances:

Year:  2014        PMID: 24966580      PMCID: PMC4051953          DOI: 10.3748/wjg.v20.i22.7067

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo.

Authors:  A Khanna; A E Morelli; C Zhong; T Takayama; L Lu; A W Thomson
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

2.  Weaning of immunosuppression in living donor liver transplant recipients.

Authors:  M Takatsuki; S Uemoto; Y Inomata; H Egawa; T Kiuchi; S Fujita; M Hayashi; T Kanematsu; K Tanaka
Journal:  Transplantation       Date:  2001-08-15       Impact factor: 4.939

Review 3.  Chemokines in liver inflammation and fibrosis.

Authors:  Fabio Marra
Journal:  Front Biosci       Date:  2002-09-01

4.  The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C.

Authors:  Andrea Bonacchi; Ilaria Petrai; Raffaella M S Defranco; Elena Lazzeri; Francesco Annunziato; Eva Efsen; Lorenzo Cosmi; Paola Romagnani; Stefano Milani; Paola Failli; Giacomo Batignani; Francesco Liotta; Giacomo Laffi; Massimo Pinzani; Paolo Gentilini; Fabio Marra
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

Review 5.  Reducing the risks of cardiovascular disease in liver allograft recipients.

Authors:  George Mells; James Neuberger
Journal:  Transplantation       Date:  2007-05-15       Impact factor: 4.939

6.  Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis.

Authors:  Chundong Yu; Fen Wang; Chengliu Jin; Xinqiang Huang; David L Miller; Claudio Basilico; Wallace L McKeehan
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

7.  Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression.

Authors:  José A Pons; José Yélamos; Pablo Ramírez; María Oliver-Bonet; Alicia Sánchez; Manolo Rodríguez-Gago; Joaquima Navarro; Juan Bermejo; Ricardo Robles; Pascual Parrilla
Journal:  Transplantation       Date:  2003-04-15       Impact factor: 4.939

Review 8.  Clinical trials of transplant tolerance: slow but steady progress.

Authors:  Jeffrey B Matthews; Eleanor Ramos; Jeffrey A Bluestone
Journal:  Am J Transplant       Date:  2003-07       Impact factor: 8.086

9.  Chronic renal failure after transplantation of a nonrenal organ.

Authors:  Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

10.  Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.

Authors:  René Adam; Paul McMaster; John G O'Grady; Denis Castaing; Jurgen L Klempnauer; Neville Jamieson; Peter Neuhaus; Jan Lerut; Mauro Salizzoni; Stephen Pollard; Ferdinand Muhlbacher; Xavier Rogiers; Juan Carlos Garcia Valdecasas; Joaquin Berenguer; Daniel Jaeck; Enrique Moreno Gonzalez
Journal:  Liver Transpl       Date:  2003-12       Impact factor: 5.799

View more
  3 in total

1.  Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet.

Authors:  Yasushi Horai; Hiroyuki Utsumi; Yuko Ono; Toshimitsu Kishimoto; Yuuichi Ono; Atsushi Fukunari
Journal:  Int J Exp Pathol       Date:  2016-03-31       Impact factor: 1.925

2.  Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1.

Authors:  Naoki Muguruma; Koichi Okamoto; Tadahiko Nakagawa; Katsutaka Sannomiya; Shota Fujimoto; Yasuhiro Mitsui; Tetsuo Kimura; Hiroshi Miyamoto; Jun Higashijima; Mitsuo Shimada; Yoko Horino; Shinya Matsumoto; Kenjiro Hanaoka; Tetsuo Nagano; Makoto Shibutani; Tetsuji Takayama
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

3.  Liver Fibrosis and Inflammation under the Control of ERK2.

Authors:  Kuo-Shyang Jeng; Ssu-Jung Lu; Chih-Hsuan Wang; Chiung-Fang Chang
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.